Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.
Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.